Was the Acrivon (ACRV) CFO’s share sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked, and no footnote describes a 10b5-1 trading plan . The transaction instead is specifically described as an automatic sale to satisfy mandatory tax withholding upon vesting of restricted stock units.

Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes

Q: What price did Acrivon (ACRV) CFO Adam D. Levy receive for the sold shares?

The reported transaction shows a sale price of $1.57 per share for 1,142 shares of Acrivon common stock. The sale was coded as occurring in an open market or private transaction and was undertaken to meet mandatory tax withholding obligations.

Q: Does the Acrivon (ACRV) Form 4 report any option exercises or derivative transactions?

This Form 4 reports only a non-derivative common stock sale of 1,142 shares by the CFO. The derivative section shows no transactions or remaining derivative positions in this particular filing, focusing solely on the compensation-related tax withholding sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported a sale of 1,142 shares of common stock on August 4, 2026 at $1.57 per share. The shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and he now directly holds 66,008 shares.

Insider Trade Summary

Net Seller: 1,142 shares

Net Sell 1 txn

Insider Levy Adam D.

Role Chief Financial Officer

Sold 1,142 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	1,142	$1.57	$2K

Holdings After Transaction: Common Stock — 66,008 shares (Direct)

Footnotes (1)

F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Key Figures

Shares sold: 1,142 shares Sale price: $1.57 per share Shares held after sale: 66,008 shares +2 more

5 metrics

Shares sold 1,142 shares Common stock sale reported on August 4, 2026

Sale price $1.57 per share Price for the 1,142 common shares sold

Shares held after sale 66,008 shares Direct common stock holdings following the transaction

Reported sale transactions 1 Number of non-derivative sale transactions in this Form 4

Net shares sold 1,142 shares Net buy/sell shares across reported transactions

Key Terms

restricted stock units, mandatory tax withholding, open market or private transaction

3 terms

restricted stock units financial

"upon vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"Shares sold automatically to satisfy the mandatory tax withholding."

open market or private transaction financial

"Sale in open market or private transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 04:34 PM Accepted by SEC EDGAR 08/06/2026 - 04:34 PM

FAQ

What insider transaction did Acrivon (ACRV) report for CFO Adam D. Levy?

Acrivon reported that Chief Financial Officer Adam D. Levy sold 1,142 shares of common stock at $1.57 per share on August 4, 2026, in a transaction linked to tax obligations from vested restricted stock units.

Why were Adam D. Levy’s Acrivon (ACRV) shares sold in this Form 4?

The filing states the shares were sold automatically to satisfy mandatory tax withholding requirements triggered when restricted stock units vested. This indicates the transaction was tied to compensation-related tax obligations rather than a discretionary portfolio decision.

How many Acrivon (ACRV) shares does CFO Adam D. Levy hold after the reported sale?

After the reported transaction, Adam D. Levy directly holds 66,008 shares of Acrivon common stock. This figure reflects his remaining direct ownership following the automatic sale of 1,142 shares to cover tax withholding on vested restricted stock units.

What price did Acrivon (ACRV) CFO Adam D. Levy receive for the sold shares?

The reported transaction shows a sale price of $1.57 per share for 1,142 shares of Acrivon common stock. The sale was coded as occurring in an open market or private transaction and was undertaken to meet mandatory tax withholding obligations.

Does the Acrivon (ACRV) Form 4 report any option exercises or derivative transactions?

This Form 4 reports only a non-derivative common stock sale of 1,142 shares by the CFO. The derivative section shows no transactions or remaining derivative positions in this particular filing, focusing solely on the compensation-related tax withholding sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Adam D.

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/04/2026		S⁽¹⁾		1,142	D	$1.57	66,008	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR